Detalhe da pesquisa
1.
Hydantoin based inhibitors of MMP13--discovery of AZD6605.
Bioorg Med Chem Lett
; 23(16): 4705-12, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23810497
2.
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.
Bioorg Med Chem Lett
; 22(1): 271-7, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22153941
3.
Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods.
ACS Chem Biol
; 17(1): 54-67, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34955012
4.
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
J Med Chem
; 65(14): 9662-9677, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35838760
5.
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.
Bioorg Med Chem Lett
; 21(5): 1376-81, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21300546
6.
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.
Bioorg Med Chem Lett
; 21(11): 3301-6, 2011 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21536437
7.
Selective non zinc binding inhibitors of MMP13.
Bioorg Med Chem Lett
; 21(14): 4215-9, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21669521
8.
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
J Med Chem
; 64(20): 15189-15213, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647738
9.
Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply.
Org Process Res Dev
; 24(6): 940-976, 2020 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556267
10.
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
J Med Chem
; 63(24): 15564-15590, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306391
11.
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
J Med Chem
; 50(9): 2213-24, 2007 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-17373783
12.
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
J Med Chem
; 49(3): 955-70, 2006 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-16451062
13.
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res
; 76(11): 3307-18, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27020862
14.
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 58(8): 3522-33, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25790336
15.
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
J Med Chem
; 58(20): 8128-40, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26407012
16.
Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
J Med Chem
; 57(11): 4661-76, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24785301
17.
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 59(7): 3576, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27003331
18.
Construction of perhydro indol-2-ones by a methoxide catalyzed deacetylation-Michael-aldol cascade.
Chem Commun (Camb)
; 46(10): 1691-3, 2010 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20177618